Palmer, Daniel H.
Valle, Juan W. http://orcid.org/0000-0002-1999-0863
Ma, Yuk Ting
Faluyi, Olusola
Neoptolemos, John P.
Jensen Gjertsen, Trine
Iversen, Berit
Amund Eriksen, Jon
Møller, Anne-Sophie
Aksnes, Anne-Kirsti
Miller, Robert
Dueland, Svein
Funding for this research was provided by:
Targovax ASA, The Research Council of Norway, Innovation Norway
Article History
Received: 9 May 2019
Revised: 21 January 2020
Accepted: 31 January 2020
First Online: 17 February 2020
Ethics approval and consent to participate
: Ethical approval was obtained in each of the participating countries. The study conformed to the principles of the Declaration of Helsinki and International Conferences on Harmonisation on Good Clinical Practice. All patients provided written informed consent before study inclusion. In the United Kingdom, the study was approved by NRES Committee West Midlands—Coventry and Warwickshire (reference number: 13/WM/0421). In Norway, the study was approved by REK sør-øst C (reference number: 2012/1147/REK sør-øst C).
: Not applicable. No patient personal identifying data or images are included in this paper.
: The data in this publication are commercially confidential. Data requests should be made to the corresponding author.
: The authors declare no competing interests.
: This study was funded by Targovax ASA, The Research Council of Norway and Innovation Norway. Infrastructure support was provided by Liverpool Experimental Cancer Medicine Centre.